Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
Top Cited Papers
- 1 November 2002
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 90 (10) , 1092-1097
- https://doi.org/10.1016/s0002-9149(02)02798-4
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studiesClinical Therapeutics, 2001
- Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitorEuropean Heart Journal Supplements, 2001
- Effect of ezetimibe on serum concentrations of lipid-soluble vitaminsAtherosclerosis Supplements, 2001
- Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trialAtherosclerosis Supplements, 2001
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000
- Colesevelam Hydrochloride (Cholestagel)Archives of internal medicine (1960), 1999
- Comparison of two scoring systems used to monitor diets in outpatient clinical trialsJournal of Cardiovascular Risk, 1995
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972